Enveric Biosciences
The company offers in-clinic treatments which come in high doses which can provide benefit for months, the treatment is associated with hallucinations, is time-consuming and appropriate for a limited pateient population. The company also has a prescription model which contains a moderate dose which is taken reglarly with minimal side effects and reduced hallucinations with the treatment being available to a large patient population.
The Psybrary contains over 500 potential neuroplastogen drug candidates. Psybrary candidates have been demonstrated to bind to numerous serotonin receptors.
EB-003 has received US Patent 11,752,130 and US Patent 11,845,727 as well as 6 notices of allowance. EB-002 has received US Patent 11,707,447; and US Patent 11,845,726.
DRUG PROGRAMS TARGET: Supportive care indications that include radiodermatitis, chemotherapy-induced neuropathy, glioblastoma as well as sleep and mood disorders.
SUBSTANCE FOCUS: Mescaline Derivatives, Psilocin, MDMA, neuroplastogens, NSRI and SNDRI.
NEWS & PARTNERSHIPS:
2021
The company launched a strategic development collaboration and exclusive supply agreement with PureForm Global to work exclusively to support Enveric’s development plans in the cancer treatment and supportive care space, with Enveric owning the IP.
The company acquired an exclusive, perpetual license from Diverse Biotech, a biopharmaceutical company focused on developing new molecules for treating oncology and other debilitating diseases. Enveric plans to research and develop these new drugs with the goal of alleviating the side effects that cancer patients experience. The company adds to the Company’s list of target indications by obtaining 5 molecules, 4 of which are dermatology-focused and 1 that is pain-focused. Enveric will also gain access to Diverse Biotech’s scientists and formulators to help synthesize and validate these drugs, as the company moves through pre-clinical and clinical activities.
The company acquired MagicMed Industries, a privately held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, DMT and other molecular derivatives with applications across multiple indications.
2022
The company is working with the University of Calgary’s Hotchkiss Brain Institute, a leading neurosciences center of excellence, at the Cumming School of Medicine in Calgary, Canada that is dedicated to advancing brain and mental health research and education, to establish a groundbreaking clinical trial of EVM-101 for the treatment of Cancer Related Distress.
The company formed a scientific advisory board which will advise Enveric on the company’s technology capabilities, innovation pipeline, early-stage candidate prioritization, and partnering opportunities. Additionally, the SAB will provide insights on emerging trends in neuroscience and technology, as well as the potential implications for advancing the company’s pipeline of psychedelic-inspired new drug candidates for patients suffering from mental health diseases.
2023
The company received US Patent No. 11,707,441 and 11,707,447 titled “C4-Carbonothioate-substituted Tryptamine Derivatives and Methods of Using,” pertaining to the Company’s lead candidate EB-373, a psilocin prodrug being developed for the treatment of anxiety disorder.
The company was awarded US Patent No. 11,746,087, titled “C-4 Carboxylic Acid Substituted Tryptamine Derivatives and Methods of Using,” pertaining to the Company’s EVM201 Series and lead candidate EB-373, a psilocin prodrug being developed for the treatment of anxiety disorder.
The company was awarded US Patent No. 11,752,130, titled “Carboxylated Psilocybin Derivatives and Methods of Using,” pertaining to the Company’s EVM301 Series of molecules being developed as potential treatments for mental health disorders.
The company announced over 1000 psychedelic-inspired therapeutic candidates in its Psybrary.
The company announced new research detailing the first-ever isolation of a novel indolethylamine N-methyltransferase from the Cane Toad (Rhinella Marina) and the successful development of a bioproduction platform for the isolation and pharmacological screening of novel indolethylamines.
The company established Enveric Therapeutics in Australia to support the company’s plans to advance its EVM201 Series including lead candidate EB-373, towards the clinic.
The company entered into an agreement with Avance Clinical, an Australia-based contract research organization for its planned Phase 1 clinical trial of EB-373.
2024
The company announced a licensing agreement with Aries Science & Technology for the clinical development of Enveric’s patented radiation dermatitis topical product. Enveric will be eligible to receive aggregate milestone payments of up to $61 million, as well as tiered royalties ranging from 2.5% to 10% on future sales, if all conditions are met.
The company was granted Patent No. 11,945,778 by the United States Patent and Trademark Office, expanding its protection for potential clinical indications for its EB-002 drug candidate.
The company was awarded US Patent No. 11,918,594, titled “Multi-Substituent Psilocybin Derivatives”.
The company agreed to sell one of its cancer-related patent portfolios for an undisclosed amount. The patents and applications being sold disclose and claim the synergistic combination of cannabidiol and second therapeutic agents for the treatment of cancer. The divested portfolio includes patents issued in the U.S., Australia, Canada, China, Europe, and Japan, with patent applications pending in Canada, Israel, and Korea. Enveric retains no ownership rights in the divested portfolio, any companies owned by, or to be formed by the recipients.
The company outlicensed its EVM201 program, including drug candidate EB-002 to MycoMedica Life Sciences for mental health treatment advancements for which the company will receive cash and royalties, depending upon milestones achieved. EB-002 is exclusively licensed to MycoMedica globally including its formulations, usage methods and associated medical devices. MycoMedica will assume responsibility for all future preclinical, clinical, and commercial development of EB-002. The agreement allows for sublicensing and cash buyout options.
The company unveiled 57 unique product opportunities in 7 distinct molecule classes all protected by the company’s IP found through its Psybrary platform using PsyAI.
The company signed 3 non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of three classes of compounds.
The company signed 2 non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of cannabinoid-COX-2 conjugate compounds for both pharmaceutical and non-pharmaceutical applications for treatment of joint diseases.
The company was awarded US Patent No. 11,918,594, titled “Multi-Substituent Psilocybin Derivatives” and US Patent No. 11,931,338, titled “Nitrilated Psilocybin Derivatives”.
The company signed a licensing agreement with Aries Science & Technology to exclusively out-license two patent families of Methods for Treating Breast Cancer and Other Cancers for development through additional discovery and preclinical stages using cannabinoids in combination with chemotherapeutic drugs to treat cancer. The licensee will pay a license execution fee as well as development and sales milestones up to $61 Million and royalties range from 2.5-10% on all future sales and includes exclusive global licenses to the methods, devices and drugs developed to practice the methods which feature using cannabinoids in combination with chemotherapeutic drugs and will assume responsibility for all future preclinical and clinical development on a royalty-bearing basis for all human and animal pharmaceutical applications. The licensee is also given a buyout option.
The company signed a non-binding term sheet to out-license a class of Novel Psilocin Prodrugs to Vancouver, BC-based MindBio Therapeutics.
The company was awarded Patent No. 11,945,778 by the United States Patent and Trademark Office pertaining to EB-002.
The company was awarded US Patent, No. 12,133,856 and 12,138,276. The patents expand the range of protection for novel, non-obvious multi-substituent and halogenated psilocybin derivative compounds and pharmaceutical formulations containing such compounds, respectively.
The company was awarded US Patent, No. 12,065,404 and 12,077,498 related to its EVM201 series prodrug molecules. These patents protect novel, non-obvious C4-carboxylic acid-substituted tryptamine derivative compounds and pharmaceutical drug formulations containing such compounds, and methods of making such compounds, respectively.
The company MycoMedica will seek to develop EB-002, formerly EB-373, a synthetic prodrug of the active metabolite psilocin, in treatment of neuropsychiatric disorders such as depression. MycoMedica will receive an exclusive, global license to the formulations, drugs, method of use, and medical devices developed by Enveric to utilize the compound. MycoMedica would assume responsibility for all future preclinical, clinical, and commercial development on a royalty-bearing basis for all human and animal pharmaceutical applications. As part of the license agreement, if certain conditions are met, Enveric is eligible to receive upfront, development, and sales milestones potentially totaling up to $62 million, plus tiered single digit royalties on all future sales. The license grants sublicensing rights and cash buyout options to MycoMedica.
Enveric in partnership with Aries announced US Patent No. 12,059,393 to Akos Biosciences, Enveric’s wholly-owned subsidiary.
2025
Akos Biosciences entered into 2 licensing agreements with Restoration Biologics. The two licenses grant Restoration Biologics use of the technology for all human and animal applications. Restoration Biologics initially plans to focus on joint pathology, such as osteoarthritis and rheumatoid arthritis. The two exclusive, royalty-bearing global licenses provide full control to Restoration Biologics to develop, market, and commercialize the conjugate compounds, which are novel chemical structures that include cannabinoids in conjugate form with COX-2 inhibitors and cannabinoids in conjugate form with selected steroids. Enveric may receive future development and sales milestone payments, assuming certain conditions are met, including successful product development and commercialization. Royalty rate percentages are tiered, depending on meeting certain sales criteria, and range from low single digit to low double digits on future sales.
The company was awarded US Patent No. 12,195,439: “Cl-Substituted Isopropylamine Fused Heterocyclic Mescaline Derivatives” issued for its EVM401 Series.
The company was awarded US Patent No. 12,428,408, titled, “Fused Heterocyclic Mescaline Derivatives” which covers a unique series of compounds, which are designed to target key serotonin receptors and drive neuroplasticity.
The company started a Requests-For-Proposal process for the licensing or sales of its PsyAI trademark portfolio as the asset does no longer hold a strategic purpose as the company is focusing on drug development. The company also announced 2 expressions of interest in the licensing or sale of the portfolio of PsyAI trademarks.
2026
The company’s subsidiary Akos Biosciences licensed its US Trademark portfolio for RCANN and an RCANN design to TOTEC Pharma, an affiliate of Aries Science & Technology. The trademark licensing also includes an option to purchase the RCANN trademark portfolio in the future, contingent on TOTEC meeting certain development and commercialization milestones.
The company received registration for 5 trademarks from the Canadian Intellectual Property Office. The registered trademarks include company house marks Enveric and Enveric Biosciences, design logos for packaging Plus Marks (2 designs) and the phrase Next Generation Mental Health.
The company received US Patent No. 12,577,232 (“N-heterocycle substituted tryptamine derivatives and methods of using,”) pertaining to its EVM301 series of molecules including EB-003.
The company announced the issuance of US Patent No. 12,605,361 (“Carboxylated Psilocybin Derivatives and Methods of Using,”) pertaining to the Company’s EVM301 Series of molecules being developed as potential treatments for mental health disorders.
The company announced confirmation of US Patent No. 12,605,361 titled “Carboxylated Psilocybin Derivatives and Methods of Using,” pertaining to the Company’s EVM301 Series of molecules being developed as potential treatments for mental health disorders.